Maxigen Biotech Overview
Get informed when a big investor buys or sells
+ Follow19.43%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 1783.TW is 19.43%. That is above the sector sector average of 11.85%. Investors often review this figure alongside Maxigen Biotech's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, 1783.TW currently prints 19.43% for ROE, while the sector average sits near 11.85%. That is roughly 63.9% above the sector mean. Large gaps often invite a closer look at Maxigen Biotech's growth, margins, and balance sheet.
Return on Equity shows how effectively Maxigen Biotech converts resources into returns. At 19.43%, 1783.TW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 1783.TW's ROE (19.43%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
